Shots:

• The P-III STAR study involves assessing the safety and efficacy of a single subretinal injection of timrepigene emparvovec (BIIB111/AAV2-REP1) in 169 adult males with a genetically confirmed diagnosis of choroideremia
• The study did not meet its 1EPs i.e. improvement of at least 15 letters from baseline in BCVA @12mos. post-treatment as measured by the ETDRS chart. The study also failed to meet its 2EPs- safety results were consistent with previous studies
• Biogen will evaluate the complete data set before confirming the next steps for the timrepigene emparvovec clinical program

  | Ref: GlobeNewswire | Image: Biogen